1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Regen BioPharma, Inc.

Regen BioPharma, Inc.

RGBPP
Regen BioPharma, Inc.US flagOther OTC
0.00
USD
+0.00
- -
198,711.00Market Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
-1,030.87
-2,956.96
-2,282.62
-1,425.78
-687.99
-190.29
-117.28
-144.2
-290.39
-176.37
-143.11
-367.41
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
-2
-3
-6
-5
-3
3
-7
2
1
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-1,151.41
-3,413.52
-5,308.22
-4,715.2
-2,384.71
2,483.21
-3,951.79
945.59
432.66
-282.49
-538.76
-302.54
Working Capital
- -
- -
- -
-1
-5
-9
-11
-7
-14
-8
-5
-5
-6
-5
LT Debt
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
-1
-5
-9
-11
-7
-13
-8
-5
-5
-6
-5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
-23.31
- -
-12.7
-5.69
- -
- -
2.05
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
108
351
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
7
6
Payables & Accruals
2
2
2
ST Debt
1
1
1
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
138.88%
5.91%
20.39%
Free Cash Flow
-613.67%
-1,200.03%
-48.96%
Net Income, GAAP
-75.15%
-121.84%
90.72%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
David Raymond Koos
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
4700 Spring Street La Mesa CA United States of America 91942
IPO Date
Apr 20, 2016
CIK
0001589150
Website
regenbiopharmainc.com
Similar Companies
SkinBioTherapeutics Plc (SBTX.L)
Carmell Therapeutics Corporation (CTCXW)
Cocrystal Pharma, Inc. (COCP)
Newron Pharmaceuticals S.p.A. (NWRN.SW)
Nxera Pharma Co., Ltd. (SOLTF)
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
Business
Regen BioPharma, Inc. (OTC: RGBPP) is a publicly traded biotechnology company focused on developing innovative regenerative medical applications, including autologous cell therapies, RNA- and DNA-based immunotherapies, and small molecules targeting immune-oncology and autoimmune disorders. The company advances novel technologies through pre-clinical and Phase I/II clinical trials, with a primary emphasis on modulating the immune checkpoint NR2F6 to treat cancer and autoimmune diseases; its pipeline features HemaXellerate, a stem cell-derived therapy for repairing damaged bone marrow in aplastic anemia and chemotherapy/radiation-treated patients; dCellVax and tCellVax, dendritic cell-based immunotherapies using gene silencing to stimulate immune responses; Dura-CAR, CAR-T cells enhanced with shRNA to inhibit NR2F6 for durable effectiveness; KimerApt, a platform of dual-function aptamers that bind and inhibit receptors like antibodies; DiffronC, small molecules and gene silencing for blood disorders; and BORIS, patented approaches modulating cancer stem cell processes. Founded in 2012 and headquartered in La Mesa, California, Regen BioPharma operates primarily in the United States, targeting niche markets such as rare hematological disorders and oncology with protected intellectual property encompassing 11 issued patents and 17 pending. Recent developments include FDA clearance for a Phase 1 trial of HemaXellerate, announced in 2024, with partnerships established with a leading clinical research organization for trial execution expected within 12-14 months; an ongoing Orphan Drug Designation application for HemaXellerate to secure regulatory benefits like tax credits and market exclusivity; and presentations at the Emerging Growth Conference highlighting expansion into chemotherapy-induced bone marrow suppression markets valued over $1 billion.